This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wesche, M. F. T. Articles by Wiersinga, W. M. Search for Related Content PubMed PubMed Citation Articles by Wesche, M. F. T. Articles by Wiersinga, W. M.

A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter

Departments of Endocrinology and Metabolism (M.F.T.W., W.M.W.), Nuclear Medicine (M.M.C.T.-v.-B.), and Radiodiagnostics (N.J.S.), Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam; and Department of Endocrinology (P.L.), Academic Hospital of the Free University, 1007 MB Amsterdam, The Netherlands

Address correspondence and requests for reprints to: Prof. Dr. W. M. Wiersinga, Department of Endocrinology and Metabolism F5.171, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

A randomized clinical trial was performed in consecutive patients with sporadic nontoxic nodular goiter to compare efficacy and side effects of iodine-131 (¹³¹I) therapy with suppressive levothyroxine (L-thyroxine) treatment. Sixty-four patients were randomized after stratification for sex and menopausal age to receive ¹³¹I (4.44 MBq/g thyroid; group A) or suppressive L-thyroxine treatment aiming at TSH values between 0.01 and 0.1 mU/L (group B). The main outcome measurements after 2 yr were goiter size by ultrasound, serum thyroid function tests, markers of bone turnover, and bone mineral density (BMD). Fifty-seven patients completed the trial. Goiter size was reduced after 2 yr by 44% in group A and by 1% in group B (P < 0.001). Nonresponders (goiter reduction <13%) were 1 of 29 patients in group A and 16 of 28 patients in group B (P = 0.00001). In responders, goiter reduction in group A (46%) was greater than in group B (22%; P < 0.005). In group A, 45% of patients developed hypothyroidism. In group B, 10 patients experienced thyrotoxic symptoms, requiring discontinuation of treatment in 2 (in 1 because of atrial fibrillation). Markers of bone formation and bone resorption increased significantly in group B, related to a mean decrease of 3.6% of BMD at the lumbar spine after 2 yr (from 1.09 ± 0.22 to 1.05 ± 0.23 g/cm²; P < 0.001), both in pre- and postmenopausal women. No changes in BMD were observed in group A. In conclusion, ¹³¹I therapy is more effective and better tolerated than L-thyroxine treatment in patients with sporadic nontoxic goiter. Suppressive L-thyroxine treatment results in significant bone loss.

This article has been cited by other articles:

				S. Fast, V. E. Nielsen, S. J. Bonnema, and L. Hegedus Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy Eur. J. Endocrinol., April 1, 2009; 160(4): 517 - 528. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, V. E. Nielsen, H. Boel-Jorgensen, P. Grupe, P. B. Andersen, L. Bastholt, and L. Hegedus Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3424 - 3428. [Abstract] [Full Text] [PDF]

				J. Tajiri Radioactive Iodine Therapy for Goitrous Hashimoto's Thyroiditis J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4497 - 4500. [Abstract] [Full Text] [PDF]

				V. E. Nielsen, S. J. Bonnema, H. Boel-Jorgensen, P. Grupe, and L. Hegedus Stimulation With 0.3-mg Recombinant Human Thyrotropin Prior to Iodine 131 Therapy to Improve the Size Reduction of Benign Nontoxic Nodular Goiter: A Prospective Randomized Double-blind Trial. Arch Intern Med, July 24, 2006; 166(14): 1476 - 1482. [Abstract] [Full Text] [PDF]

				C. C. Albino, C. O. Mesa Jr., M. Olandoski, C. E. Ueda, L. C. Woellner, C. A. Goedert, A. M. Souza, and H. Graf Recombinant Human Thyrotropin as Adjuvant in the Treatment of Multinodular Goiters with Radioiodine J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2775 - 2780. [Abstract] [Full Text] [PDF]

				W.-A. Nieuwlaat, A. R. Hermus, H. A. Ross, W. C. Buijs, M. A. Edelbroek, J. W. Bus, F. H. Corstens, and D. A. Huysmans Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., April 1, 2004; 45(4): 626 - 633. [Abstract] [Full Text] [PDF]

				W.-A. Nieuwlaat, D. A. Huysmans, H. C. van den Bosch, C. G. (F. Sweep, H. A. Ross, F. H. Corstens, and A. R. Hermus Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3121 - 3129. [Abstract] [Full Text] [PDF]

				L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbak, P. W. Ladenson, and L. Hegedus Management of the Nontoxic Multinodular Goiter: A North American Survey J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 112 - 117. [Abstract] [Full Text] [PDF]

				Thyroxine vs. Radioactive Iodine for Sporadic Nontoxic Goiter Journal Watch (General), April 3, 2001; 2001(403): 4 - 4. [Full Text]

				M. H. Samuels Editorial: Evaluation and Treatment of Sporadic Nontoxic Goiter--Some Answers and More Questions J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 994 - 997. [Full Text]